Market Place
Sourcing Support
Strong Cresemba Sales In Asia Pacific Triggers 4th Milestone Payment
10 Oct 2024 //
GLOBENEWSWIRE
Basilea Starts Phase 3 Study Of Fosmanogepix In Candidiasis
23 Sep 2024 //
GLOBENEWSWIRE
Basilea Partners With BARDA For Novel Antimicrobials
19 Sep 2024 //
GLOBENEWSWIRE
Basilea Gets $268M BARDA Deal For Antimicrobials
19 Sep 2024 //
FIERCE BIOTECH
Cresemba Sales Trigger in Europe USD 25 Million Milestone Payment
06 Sep 2024 //
GLOBENEWSWIRE
EU Approves Pediatric Use of Cresemba®; CHF 10M Milestone Payment to Basilea
27 Aug 2024 //
GLOBENEWSWIRE
EC Approves Pediatric Use Of Cresemba, Triggering CHF 10M Payment To Basilea
27 Aug 2024 //
GLOBENEWSWIRE
Basilea Receives Milestone Payment For Strong Cresemba Sales In Asia Pacific
21 Aug 2024 //
GLOBENEWSWIRE
Basilea Reports Strong H1 2024 Results, Increases Full-Year Guidance
12 Aug 2024 //
GLOBENEWSWIRE
Basilea Partners With Glioblastoma Foundation For Lisavanbulin Development
20 Jun 2024 //
GLOBENEWSWIRE
Basilea Presents New Ceftobiprole Data At ESCMID Global 2024
03 May 2024 //
GLOBENEWSWIRE
Basilea AGM Approves All Board Proposals
24 Apr 2024 //
GLOBENEWSWIRE
Basilea’s Zevtera will play unique yet critical role in MRSAB: GlobalData
15 Apr 2024 //
EXPRESSPHARMA
Basilea Awarded CARB-X Grant to Develop Antibiotics
09 Apr 2024 //
PRESS RELEASE
FDA Approves New Antibiotic for Three Different Uses
04 Apr 2024 //
FDA
Continued strong Cresemba sales performance in Asia Pacific
11 Mar 2024 //
GLOBENEWSWIRE
Basilea reports strong 2023 full-year results
13 Feb 2024 //
GLOBENEWSWIRE
Cresemba sales in Latin America trigger first sales milestone payment to Basilea
19 Jan 2024 //
GLOBENEWSWIRE
Basilea announces acquisition of preclinical antibiotics program from Spexis
15 Jan 2024 //
GLOBENEWSWIRE
Basilea provides portfolio status update
05 Jan 2024 //
GLOBENEWSWIRE
Basilea announces accelerated loan repayment
19 Dec 2023 //
GLOBENEWSWIRE
Basilea announces that FDA approves expanded use of antifungal Cresemba
11 Dec 2023 //
GLOBENEWSWIRE
Continued strong Cresemba (isavuconazole) sales performance in Asia Pacific
20 Nov 2023 //
GLOBENEWSWIRE
Basilea announces acquisition of fosmanogepix
13 Nov 2023 //
GLOBENEWSWIRE
Basilea continues pipeline refill with Pfizer antifungal
13 Nov 2023 //
FIERCE BIOTECH
Basilea announces agreement for first-in-class antibacterial agent
31 Oct 2023 //
PRESS RELEASE
Basilea announces acquisition of novel clinical-stage antifungal
19 Oct 2023 //
GLOBENEWSWIRE
Basilea reports new data for Zevtera presented at US IDWeek Congress 2023
17 Oct 2023 //
GLOBENEWSWIRE
Basilea announces FDA acceptance of NDA for antibiotic ceftobiprole
02 Oct 2023 //
GLOBENEWSWIRE
Basilea announces publication of phase 3 data on ceftobiprole
28 Sep 2023 //
GLOBENEWSWIRE
Basilea reports strong revenue and profit growth in first half-year 2023
15 Aug 2023 //
GLOBENEWSWIRE
Basilea announces submission of a NDA to the US FDA for antibiotic ceftobiprole
04 Aug 2023 //
GLOBENEWSWIRE
Continued strong Cresemba sales by Pfizer trigger USD 26 million sales
08 Jun 2023 //
GLOBENEWSWIRE
Basilea shareholders approve all proposals of the board of directors
26 Apr 2023 //
GLOBENEWSWIRE
Basilea provides update on NEW to the USFDA for antibiotic ceftobiprole
18 Apr 2023 //
GLOBENEWSWIRE
Basilea announces CHF 5 Mmilestone payment from Asahi Kasei fo isavuconazole)
23 Mar 2023 //
GLOBENEWSWIRE
Basilea reports financial results 2022 based on implementation of new strategy
14 Feb 2023 //
GLOBENEWSWIRE
Continued Cresemba sales triggers second sales milestone payment to Basilea
07 Feb 2023 //
GLOBENEWSWIRE
Basilea reports preliminary operating profit for 2022
24 Jan 2023 //
GLOBENEWSWIRE
Basilea hands back antifungal 9 months after licensing it
17 Jan 2023 //
FIERCE BIOTECH
Basilea reports 2022 revenues, exceeding guidance, & provides portfolio update
11 Jan 2023 //
GLOBENEWSWIRE
Continued strong Cresemba sales by Astellas in the U.S. trigger CHF 20 million
09 Jan 2023 //
GLOBENEWSWIRE
Basilea announces regulatory approval of antifungal Cresemba
23 Dec 2022 //
GLOBENEWSWIRE
Basilea announces transition milestone for oncology asset BAL0891
19 Dec 2022 //
GLOBENEWSWIRE
Basilea announces sale of preclinical oncology program to Twentyeight-Seven
01 Nov 2022 //
GLOBENEWSWIRE
ERADICATE phase 3 study results highlight the potential role of ceftobiprole
24 Oct 2022 //
GLOBENEWSWIRE
Basilea announces late breaking presentation on successfully completed ERADICATE
13 Oct 2022 //
GLOBENEWSWIRE
SillaJen to acquire rights for Basilea’s novel kinase inhibitor, BAL0891
21 Sep 2022 //
PHARMABIZ
Basilea announces closing of CHF 75M secured loan agreement with Athyrium
20 Sep 2022 //
GLOBENEWSWIRE
Basilea sheds another oncology program as anti-infectives pivot plows forward
20 Sep 2022 //
ENPTS
Basilea announces acquisition of rights for oncology asset BAL0891
19 Sep 2022 //
GLOBENEWSWIRE
Basilea hands off preclinical oncology program for $248M
08 Sep 2022 //
ENDPTS
Basilea announces sale of preclinical oncology program to Nodus Oncology
07 Sep 2022 //
GLOBENEWSWIRE
Basilea announces CHF 75 million senior secured loan agreement with Athyrium
07 Sep 2022 //
GLOBENEWSWIRE
Basilea reports strong financial half-year results
16 Aug 2022 //
GLOBENEWSWIRE
Basilea announces Zevtera (ceftobiprole) marketing authorization in Brazil
11 Jul 2022 //
GLOBENEWSWIRE
Basilea returns cancer drug rights to Merck
28 Jun 2022 //
FIERCEBIOTECH
Basilea`s positive results of PIII ERADICATE study with ceftobiprole in SAB
27 Jun 2022 //
GLOBENEWSWIRE
Basilea reports progress on strategy implementation to focus on anti-infectives
27 Jun 2022 //
GLOBENEWSWIRE
Basilea announces approval for additional formulation of antifungal Cresemba
24 Jun 2022 //
GLOBENEWSWIRE
